For the Inventor, By the Inventor

Enter assignee name

Waltham, MA, United States of America

Immunogen, Inc.

USPTO Granted Patents = 255

% Expired Patents = 32.5

CIPO Patents = 21

EPO Patents = 70

Trademarks = 11

Forward Citations = 6,696

Loading Chart...

Loading Chart...

132 inventors (with patents filed for the assignee):

Ravi V J Chari (90 out of 94 patents)

Michael Louis Miller (53 out of 57 patents)

Daniel J Tavares (43 out of 54 patents)

4. Wayne Charles Widdison (39 out of 39 patents)

5. Robert Yongxin Zhao (35 out of 59 patents)

6. Lingyun Rui (28 out of 36 patents)

7. Wei Li (26 out of 36 patents)

8. Manami Shizuka (24 out of 30 patents)

9. Nathan Elliott Fishkin (23 out of 28 patents)

10. Richard A Silva (21 out of 27 patents)

11. Rajeeva Singh (21 out of 21 patents)

12. Olga Ab (20 out of 20 patents)

13. Gillian Payne (18 out of 19 patents)

14. Viktor S Goldmakher (17 out of 20 patents)

15. Thomas D Chittenden (17 out of 20 patents)

Core Competencies:

Antibody Conjugates

Cytotoxic Benzodiazepines

Maytansinoid Derivatives

Immunoconjugates

Folate Receptor 1

Therapeutic Combinations

Cell-Binding Agents

Diagnostic Assays

Peptide Linkers

Cross-Linkers

Cancer Therapy

Purification Methods

255 patents: Sort by Forward Citations

1. 12390471 - Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof (2025-08-19),

2. 11981688 - Methods of preparing cytotoxic benzodiazepine derivatives (2024-05-14),

3. 11981687 - Methods of preparing cytotoxic benzodiazepine derivatives (2024-05-14),

4. RE49918 - Cytotoxic benzodiazepine derivatives (2024-04-16),

5. 11945862 - Compositions and methods for antibody production (2024-04-02),

6. 11932701 - Method for increasing the efficacy of cancer therapy by administering an anti-FOLR1 immunoconjugate (2024-03-19),

7. 11897961 - Anti-CD123 antibodies and conjugates and derivatives thereof (2024-02-13),

8. 11834498 - Biparatopic FR-alpha antibodies and immunoconjugates (2023-12-05),

9. 11833214 - Methods of preparing cell-binding agent-drug conjugates (2023-12-05),

10. 11793885 - Substituted benzo[5,6][1,4]diazepino[1,2-a]indoles for the treatment of proliferative disorders (2023-10-24),

11. 11760759 - Process for preparing substituted indolines (2023-09-19),

12. 11744900 - Preparation of maytansinoid antibody conjugates by a one-step process (2023-09-05),

13. 11732038 - Conjugates comprising cell-binding agents and cytotoxic agents (2023-08-22),

14. 11701428 - Therapeutic combinations comprising anti-CD123 immunoconjugates (2023-07-18),

15. 11591296 - Methods of preparing cytotoxic benzodiazepine derivatives (2023-02-28),

ImmunoGen, Inc. is a biotechnology company that develops targeted anticancer therapeutics. The company combines its proprietary antibody-drug conjugate technology with its expertise in the tumor biology to design and develop novel treatments for various types of cancer. ImmunoGen's innovative approach aims to deliver potent cytotoxic agents directly to cancer cells while minimizing exposure to healthy tissues, thereby reducing side effects. With a commitment to improving patient outcomes, ImmunoGen is dedicated to advancing its pipeline of potential therapies and collaborating with partners to make a meaningful impact in the field of oncology.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 22 2026

Immunogen, Inc.

255 Patents

#9 in Waltham, MA

#100 in Massachusetts

#1,682 in US

#3,419 in the World

Waltham, MA, United States of America

Immunogen, Inc.

Forward Citations = 6,696

132 inventors:

Ravi V J Chari (90 out of 94 patents)

Michael Louis Miller (53 out of 57 patents)

Daniel J Tavares (43 out of 54 patents)

4. Wayne Charles Widdison (39 out of 39 patents)

5. Robert Yongxin Zhao (35 out of 59 patents)

Please report any incorrect information to [email protected]

Loading…